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Wendy Keung1,2*, Kenneth R Boheler1,2,3 and Ronald A Li1,2,4*Abstract
Human pluripotent stem cells (hPSCs), including
embryonic and induced pluripotent stem cells, are
abundant sources of cardiomyocytes (CMs) for cell
replacement therapy and other applications such as
disease modeling, drug discovery and cardiotoxicity
screening. However, hPSC-derived CMs display immature
structural, electrophysiological, calcium-handling and
metabolic properties. Here, we review various biological
as well as physical and topographical cues that are
known to associate with the development of native CMs
in vivo to gain insights into the development of strategies
for facilitated maturation of hPSC-CMs. been developed. The EB method involves formation of
spherical cell aggregates [2] that produce cell types from allIntroduction
Despite advances in treatment, cardiovascular diseases con-
tinue to be the leading cause of death worldwide. Owing to
the non-regenerative nature of terminally differentiated
cardiomyocytes (CMs), myocardial repair remains severely
limited by the source of viable CMs for replacement.
Human pluripotent stem cells (hPSCs), including human
embryonic stem cells (hESCs) and induced pluripotent
stem cells (iPSCs), can propagate indefinitely while main-
taining their ability to differentiate into virtually all cell
types, including CMs. As such, hESCs/iPSCs provide an
unlimited ex vivo source of CMs for clinical application and
other purposes, such as drug discovery and cardiotoxicity
screening. Whereas efforts have been made to develop
highly efficient protocols for deriving hPSC-CMs, it is now* Correspondence: wkeung@hku.hk; ronaldli@hku.hk
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2014widely accepted that their functional and structural proper-
ties are immature in multiple aspects, with embryonic- or
fetal-like electrophysiological, calcium-handling and meta-
bolic signatures. Here, we review recent efforts that have
been made to understand the different biological cues for
driving maturation.Directed cardiac differentiation of human embryonic
stem cells/induced pluripotent stem cells
The first protocol of directed cardiac differentiation involves
the co-culture of hESCs with mouse visceral endoderm-like
cells (END-2) [1]. Subsequently, two methods involving
embryoid body (EB) formation or monolayer culture have
three germ layers. Early protocols depend on formation of
spontaneous contraction of the EBs, which has an efficiency
ranging from 5 to 15%. Differentiation efficiency can be
achieved by replacing serum-containing medium with
growth factors and small chemical compounds in defined
medium. Varying factors such as fetal bovine serum and
insulin free medium, mitogen-activated protein kinase inhib-
itors [3], ascorbic acid [4] and insulin-like growth factors 1
and 2 [5] has been shown to enhance cardiac progenitor cell
proliferation or CM proliferation. An improved protocol
from Keller’s group, involving addition of low bone morpho-
genetic protein (BMP)4 levels during EB formation and the
subsequent use of fibroblast growth factor 2, activin A,
vascular endothelial growth factor A and dickkopf homolog
1, yields 70% of EBs with spontaneous contraction [6]. Other
variants of this protocol involve addition of small molecule
inhibitors of WNT signaling during later stages [7]. More
developed versions that rely on EB formation have shown
greatly increased differentiation efficiency to approximately
94% spontaneously beating EBs in a number of hESC and
human iPSC lines [8]. In an improved version of this EBLtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
he article is available under the terms of the Creative Commons Attribution License
ch permits unrestricted use, distribution, and reproduction in any medium, provided
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inhibitor IWR-1 at day 4 yields over 90% CMs at day 15,
with the appearance of beating clusters as early as day 8 [9].
Besides EB formation, a monolayer method has been
developed with beating cells appearing 12 days post-
differentiation. Laflamme and colleagues [10] developed a
method where hESCs are cultured to a high confluency
and treated with high concentrations of activin A followed
by BMP4. Secreted factors are then allowed to accumulate
for 4 days and contracting cells can be seen at day 12 with
approximately 30% CMs. Improvements to this protocol
involved the addition of WNT3A at days 0 to 1 and DKK
at days 5 to 11, which improved the yield of CMs [11]. As
with EB formation, addition of small molecule WNT inhib-
itors including IWR-1 and IWP-4 at day 3 has proven
successful [12].
Our laboratory has recently developed a highly cost-
effective and efficient system for deriving hPSC-CMs from
hESC (HES2, H7, H9) and iPSC lines [13]. This protocol,
based on EB formation, requires minimal reagents (no basic
fibroblast growth factor and vascular endothelial growth
factor required) to allow cardiac differentiation with a high
efficiency for different hPSC lines. Early addition of activin
A and BMP4 and addition of Wnt inhibitor at a later time
point with ascorbic acid are sufficient to trigger CM differ-
entiation among hESC and human iPSC lines with no need
for titration of growth factors to achieve high efficiency CM
differentiation in various hPSC lines. A final output of 35
to 70 ventricular hPSC-CMs per hPSC initially seeded
for culture can be achieved, and hESC-CMs are capable
of spontaneous beating starting at day 8 after initiation
of differentiation. This simplified protocol may be easily
adapted for mass production of ventricular hPSC-CMs in
bioreactors.
Human pluripotent stem cell-derived cardiomyocytes
are structurally and functionally immature
Studies using various methods of cardiac differentiation
show that hESC-derived CMs are immature and display
fetal-like, and sometimes embryonic-like, properties [14].
Maturation of hESC-CMs is affected by cultivation time
and culture conditions as well as co-culture with other cell
types [15]. However, the effect of these modifications on
maturation remains limited and the exact mechanisms and
factors affecting maturation are still largely unknown.
hESC-CMs display embryonic- or fetal-like structures.
While adult human CMs are rod shaped with lengths in the
100 μm range, hESC-CMs are smaller in size (10 to 20 μm
in diameter) and often round [16]. These cells tend to
increase in size with prolonged time in culture; however, the
shape of these cells remains round or oblong [14,16]. In
terms of the contractile machinery, hESC-CMs show poor
contractile protein organization with very low myofibrillar
density as shown by sarcomeric α-actinin staining. Myofibrilsin these cells have random structures within the cytoplasm,
with no discernable A, I and Z bands [17]. Instead, immature
Z-bodies joining clusters of adjacent sarcomeres are
often found in hESC-CMs [14,17]. Sarcomeric length is
also considerably shorter than that found in adult CMs.
Although contractile machinery organization tends to im-
prove with long-term culture, hESC-CMs continue to display
no t-tubule [16,17] or M band formation [17], indicating that
they cannot reach a level of maturity comparable to that of
functional adult CMs. While adult CMs tend to be multinu-
cleated, hESC-CMs are mononucleated [15]. With long-term
culture, hESC-CMs tend to develop multinucleation at a
percentage that is comparable to adult CMs [17]. However,
engineered fusion of hESC-CMs does not lead to more
mature electrophysiological or calcium-handling phenotypes
(CW Kong and RAL, unpublished data). Depending on the
culturing conditions and the cell line they are derived from,
hESC-CMs may display different rates of beating, ranging
from 30 to 80 beats/minute [18]. CMs derived from hPSCs
display atrial-, ventricular- and pacemaker-like electrophysio-
logical properties, with cardiogenic preferences that are
dependent on the different hESC lines. For example, HES2
cells have been reported to be more likely to differentiate into
ventricular CMs than H1 cells [19] (Figure 1).
Mature adult CMs are electrically quiescent but excitable
upon stimulation. hESC-CMs display a greater degree of
automaticity, with the remaining quiescent cells being able
to elicit single action potentials upon stimulation [20]. Sev-
eral studies have demonstrated the immature nature of the
action potential in hESC-CMs (summarized in Figure 1E).
Maximum diastolic potential is depolarized at around -30
mV to -58 mV in early hESC-CMs and becomes hyperpo-
larized to approximately -70 mV in late hESC-CMs
[17,21-24]. This is, however, still more positive than the -80
mV normally seen in adult CMs. The upstroke velocity,
which is about 300 V/s in adult CMs [25], ranges from 2
V/s to >200 V/s in hESC-CMs, which is slower than their
adult counterparts by two to three orders of magnitude
[17,22,26]. The action potential profile in hESC-CMs is, in
general, immature and similar to that of arrhythmogenic,
failing adult ventricular CMs with a prominent ‘phase
4-like’ depolarization and a significantly depolarized resting
membrane potential [20]. Stimulation of hESC-CMs with
the β-agonist isoproterenol results in increased contraction
rate, increased amplitude of the calcium transient, and
decreased relaxation time [27]. Unlike with adult CMs,
however, increasing isoproterenol concentration produces
no ionotropic response [28,29], once again demonstrating
the immaturity of these cells.
In mature adult CMs, membrane depolarization during
an action potential leads to the opening of sarcolemmal
voltage gated L-type calcium channels, which are located at
the T-tubular network lining the sarcolemmal membrane
in close proximity to the sarcoplasmic reticulum (SR).
Figure 1 Characteristics of action potentials in human embryonic stem cell-derived cardiomyocytes. (A-D) Action potentials and percentage
distribution of ventricular, atrial and pacemaker cardiomyocytes derived from HES2 (A,B) and H1 (C,D) human embryonic stem cells (hESCs). (E) Summary
of differences in action potential properties between adult cardiomyocytes (CM) and hESC-CMs. (Adapted from Moore et al. [19]).
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turn triggers the rapid release of calcium from the SR via
ryanodine receptors (RyRs) through a mechanism known
as calcium-induced calcium release [30]. This in turn leads
to a uniform increase in cytosolic calcium, which binds to
troponin. Calcium binding causes a change in the shape of
troponin that causes tropomyosin to shift its position alongthe actin filament, thus permitting myofilament contraction
between actin and myosin. While adult CMs show a posi-
tive force-frequency relationship when paced, a negative
force-frequency relationship is observed in hESC-CMs
[20,31] (refer to Figure 2 for comparison of calcium hand-
ling between adult CMs and hESC-CMs). This suggests
that hESC-CMs possess little SR function and t-tubules,
Figure 2 Calcium handling properties in human embryonic stem cell-derived cardiomyocytes. (A,B) Schematic showing calcium signaling
pathways in adult cardiomyocytes (CM) (A) and human pluripotent stem cell-derived CMs (hPSC-CMs). hPSC-CMs show a smaller calcium transient
amplitude, slower kinetics and absence of inotropic responses compared to adult CMs due to 1) lack of junctin and triadin to facilitate ryanodine receptor
(RyR) function; 2) lack of calsequestrin for sarcoplasmic reticulum (SR) calcium buffering; 3) lack of phospholamban for sarco/endoplasmic reticulum Ca2+
ATPase (SERCA) modulation; 4) lower SERCA and RyR expression; 5) lack of T-tubules leading to U-shape of calcium propagation wavefront. (Adapted from
Li et al. [33]). (C) Summary of differences in calcium transient properties between adult CMs and human embryonic stem cell-derived CMs (hESC-CMs).
(Adapted from Kong et al. [34]).
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slowly enters the cytoplasm, to increase intracellular
calcium [16]. Reports on the degree of maturation of the
SR in hESC-CMs vary. Early studies reported that cytosolic
calcium transients in hESC-CMs do not respond to caffeine
or ryanodine, suggesting that the SR in hESC-CMs is
underdeveloped or non-functional, and that most contrac-
tion in hESC-CMs results from trans-sarcolemmal calcium
influx rather than calcium release from the SR [31]. More
recent studies from our laboratory [32] and others show
that functional SRs are present even in young hESC-CMs,
which, upon electrical stimulation, could generate Ca2+
transients similar to fetal left ventricular CMs. The ampli-
tude of the upstroke and decay velocity in hESC-CMs also
increases in long-term culture [17]. However, caffeine-
induced Ca2+ release was observed in only a small percent-
age of hESC-CMs (40% of H1- and HES2-CMs versus 60%
in fetal ventricular CMs). Ryanodine significantly reduced
the electrically evoked Ca2+ transient amplitudes and
slowed the upstroke of caffeine-responsive hESC-CMs.
By measuring thapsigargin- and tetracaine-sensitive Ca2+
sparks as the fundamental events of Ca2+ handling, wedirectly demonstrated that calcium-induced calcium release
is indeed functional in hPSC-CMs [33].
Besides having an underdeveloped SR, hESC-CMs show
a pattern of expression of key calcium handling proteins
that differs from that of adult CMs. While in adult CMs
excitation-contraction coupling is mediated mainly by
calcium-induced calcium release, in hESC-CMs it is pri-
marily due to trans-sarcolemmal influx of calcium. Calcium
transients in hESC-CMs have been shown to be dependent
on L-type calcium channels, which can be blocked more
than 80% by the specific L-type channel blocker nifedipine
[35]. The residual calcium transient elicited after the block-
ade of nifedipine is facilitated by the sodium calcium ion
exchanger NCX. As in fetal relative to adult CMs, hESC-
CMs have been shown to have an increased expression of
NCX, which works in the reverse mode to contribute to
the calcium transient [20,35]. Our laboratory shows that
NCX does not contribute to the calcium transient in
ventricular hESC-CMs as indicated by the lack of effect of
NCX inhibitors as well as its downregulation by short
hairpin RNA [33]. Other calcium handling proteins nor-
mally present in adult CMs, including calsequestrin and
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CMs [31,36], although there are reports that they are
expressed in hESC-CMs [37,38]. The expression of sarco/
endoplasmic reticulum Ca2+ ATPase (SERCA) pump in
hESC-CMs is low and comparable to the levels in fetal
CMs. However, only caffeine-sensitive CMs show a de-
crease in the decay of the calcium transient when SERCA
is inhibited by thapsigargin in hESC-CMs, suggesting that
maturation of SERCA is incomplete [32].
Immature bioenergetics and metabolism in human
embryonic stem cell derived-cardiomyocytes
Mature adult CMs have a mitochondrial volume that com-
prises over 35% of total cell volume [39,40]. Mitochondria in
these cells are aligned with myofibrillar proteins such as sar-
comeric α-actinin to form functional energetic units that fa-
cilitate energy production and excitation-contraction coupling
during myocardial contraction [41,42]. In hESC-CMs, how-
ever, mitochondrial numbers are lower [43]. Mitochondria in
these cells are also not aligned with myofibrillar proteins or
sarcomeres [15] but are concentrated around the peri-nuclear
area [44] (Figure 3A). The mitochondrial dynamic proteins
DRP-1 and OPA1 in ESC-derived CMs are also expressed at
a level that is considerably lower than in adult CMs [45].Figure 3 Immature properties of mitochondrial bioenergetics in human e
in mitochondrial properties between adult cardiomyocytes (CMs) and human em
glycolysis and oxidative metabolism in ATP production in fetal CMs, adult CMs anAdult CMs derive their energy primarily from oxidative
metabolism, with 90% of their acetyl-CoA from oxidation of
fatty acid [46]. In contrast, embryonic and fetal CMs derive
their ATP primarily through glycolysis, with oxidative
metabolism of energy substrate accounting for <15% of the
total acetyl-CoA derived from energy substrates [47]. Simi-
larly, hESC-CMs are predominantly glycolytic, highlighting
their immature and fetal like phenotypes [48], although
oxidative metabolism [43], mainly in the form of lactate
oxidation, is present [49] (Figure 3B). hESC-CMs express
oxidative phosphorylation genes, although at low levels
compared to fetal CMs [50].
Developmental cues for maturation in human
pluripotent stem cell derived-cardiomyocytes
Thyroid hormones
One type of hormone that plays an important role during
cardiac development and metabolism is thyroid hormone.
Thyroid hormones regulate metabolism and gene transcrip-
tion principally through binding of triiodothyronine (T3) to
nuclear receptors, encoded by the TRα and TRβ genes. In
rodent, T3 levels are low during the fetal period, and
increase sharply shortly after birth, while in humans T3
remains low until approximately 30 weeks of gestation, butmbryonic stem cell-derived cardiomyocytes. (A) Summary of differences
bryonic stem cell-derived CMs (hESC-CMs). (B) Relative contribution of
d hESC-CMs.
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been shown to exert effects during different stages of
cardiac development; it mediates a myosin heavy chain
isoform switch from predominantly β in the fetal stage to α
in the adult stage in mice [51,52]. However, since MHCβ is
the predominant isoform in human, this isoform switch
may not translate into functional and contractile changes
[53]. Thyroid hormone has also been shown to regulate
cardiac function by regulating the transcription of various
cardiac genes [54]. The SR proteins Ca2+ ATPase [55] and
phospholamban [56] have been shown to be upregulated by
thyroid hormone. Other sarcolemmal ion channels, includ-
ing Na+/K+ ATPase, NCX [57], and potassium channels, in-
cluding Kv1.5, Kv4.2, and Kv4.3 [58], have also been shown
to be regulated by thyroid hormones. Thyroid hormone
also increases adrenergic activity by increasing β-adrenergic
receptors, guanine-nucleotide regulatory proteins, and
adenylyl cyclases, which can also affect SR function [59,60].
These changes may account for increased adrenergic stimu-
lation in hyperthyroid patients; however, their effect during
cardiac development is poorly understood. T3 supplemen-
tation during cardiac differentiation improves cardiac
maturation in murine ESCs [61]. SR protein expression,
including expression of calcium ATPase-2a and RyR-2, have
been shown to be increased. NCX expression has also been
shown to increase. Caffeine-induced calcium transient
upstroke velocity as well as amplitude is also increased with
T3 supplementation.
Our laboratory also demonstrated that T3 supplementa-
tion after cardiac differentiation increases cell volume, and
promotes cell elongation. Action potential duration also
decreases with T3 treatment post-differentiation, suggesting
that T3 can enhance maturation both morphologically and
electrophysiologically (WK and RAL, unpublished data).
Adrenergic system
Besides thyroid hormone, adrenergic stimulation has also
been shown to be important in the growth and maturation
of the heart. During the first 2 postnatal weeks, both
catecholamine and thyroid hormone levels increase signifi-
cantly [62]. Adrenergic stimulation has been shown to
mediate both the hypertrophic response as well as beating
rates during postnatal development. Indeed, norepineph-
rine stimulates hypertrophy without hyperplasia by increas-
ing cell volume, surface area, and intracellular protein
content [63,64]. Both α-adrenergic and β-adrenergic
stimulation has been shown to mediate maturation.
α-Adrenoceptor stimulation has been shown to increase
cell mass and L-type calcium channel currents [65]. The
potassium current has also been shown to decrease with
α-adrenergic stimulation, leading to increased myocardial
contractility [66]. β-Adrenergic stimulation causes an in-
crease in the beating rate in CMs [64]. In fetal and neonatal
heart, however, β2-adrenoceptor predominates, which leadsto both lusitropic and ionotropic responses [67]. Microarray
analysis [68] shows that while β-1 adrenoceptors are
expressed at extremely low levels in hESC-CMs, as is the
case in human fetal hearts, β2 receptors are more abun-
dantly expressed, although at levels still several hundred-
fold less than in fetal hearts. However, this does suggest that
hESC-CMs may be more responsive to β2 receptor
stimulation. Indeed, various studies show that hESC-CMs
respond to isoproterenol stimulation, leading to increased
beating rate and decreases in magnitude of contraction,
suggesting that the decrease in myofilament sensitivity to
Ca2+ is greater than the increase in cytosolic Ca2+, even in
late-stage cells [28,69].
Transcriptomic, miR and epigenetic cues
Genetic and epigenetic analysis of hESC-derived CMs
reveals a number of targets that may be important for
cardiac maturation. These include a number of genes and
microRNAs (miRNAs) as well as a number of histone
modifications; however, the functional significance of these
reported changes is only beginning to be unraveled.
Transcriptome
Microarray analysis has revealed the upregulation of genes
involved in cell communication and signal transduction as
well as host defense responses in adult and fetal CMs but
not in hESC-CMs [70]. In contrast, hESC-CMs show over-
expression of genes involved in the process of cell develop-
ment, highlighting the developing processes that hESCs are
going through. Several genes that show increased expres-
sion from fetal to adult CMs are even less abundantly
expressed in hESC-CMs, suggesting they can be used as
maturation markers. These genes include the myosin genes
MYL2, MYL7, MYL3, and MYL11 as well as the cardiac
troponin genes TNNI3, TNNC1, and TNNT2 [70,71].
Calcium handling genes have also been shown to be up-
regulated in hESC-CM clusters [71]. In one study, Beqqali
and colleagues [72] identified a number of novel genes
related to cardiac differentiation in hESC-CMs, including
SRD5A2L2, SYNPO2L, THC2339346, THC1564329, and
THC1452070. These genes were expressed in human fetal
CMs, suggesting a role in cardiac development.
hESC-CMs possess a transcriptomic pattern that is
unique. Upregulation of genes exclusively in hESC-CMs
may serve as important cues for cardiac maturation in vitro
as opposed to the in vivo maturation process from fetal to
adult CMs [70]. Pathway analysis of microarray data also
reveals novel pathways that are important in the cardio-
genesis process in vitro. Genes in the focal adhesion path-
way have been shown to be upregulated in hESC-CMs [71].
These genes have been implicated in a diverse number of
cellular processes, including tissue remodeling, cell migra-
tion, embryogenesis, growth factor signaling, cell cycle pro-
gression, and cell survival. One novel pathway discovered
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network that links to the peroxisome proliferator-activated
receptor (PPAR) signaling pathway. The activation of
PPARD in this signaling pathway involves the binding of
prostaglandin I2 [3].
MicroRNA
miRNAs are a class of evolutionarily conserved small (20 to
26 nucleotides in length) non-protein-coding RNAs that
negatively regulate gene expression by affecting mRNA
stability and translation [73]. They play important roles in
the post-transcriptional regulation of gene expression, and
recent studies have established critical functions for these
miRNAs in cardiac development [74].
miR-1 is the most abundant miRNA in the mammalian
heart. It is clustered together with another miRNA,
miR-133, both of which have been found to be essential for
cardiac development. The expression of muscle contractile
proteins is tightly regulated during cardiac development
and maturation. The expression of muscle-specific myosin
genes is regulated by a group of intronic miRNAs, includ-
ing miR-208a, miR-208b and miR-499, which are embed-
ded within the introns of Myh6, Myh7 and Myh7b,
respectively [74].
Although several clusters of miRNA are important for
cardiac development and maturation, only miR-1, miR-133
and miR-499 are significantly induced during cardiac differ-
entiation in hESCs [75-78]. Moreover, miR-1, miR-144 and
miR-499 are the most differentially expressed miRNAs
between hESCs, hESC-CMs, human fetal CMs and human
adult CMs [77]. The expression of these miRNAs has since
been manipulated to facilitate maturation of hESC-CMs.
When overexpressed during pre-cardiac differentiation,
miR-1 induces expression of cardiac marker genes in
both mouse and human ESCs [78] and EBs [76,77]. Post-
differentiation, miR-1 overexpression in hESC-CMs did not
change the expression of cardiac contractile proteins, in-
cluding α-MHC and β-MHC, MLC2V, α-actinin and tropo-
nin T [77]. However, miR-1 overexpression did promote
electrophysiological maturation with a decrease in action
potential duration and a more hyperpolarized resting mem-
brane potential. This was accompanied by upregulation
of Kir2.1, Kv1.4, HERG and DHPR and downregulation of
HCN4. miR-1 overexpression also results in maturation of
calcium handling in hESC-CMs, increasing calcium transi-
ent amplitude and upstroke velocity, which is accompanied
by increased expression of junctin (Jnct), triadin (Trdn) and
ryanodine (RyR2) mRNA.
Overexpression of miR-499 in human cardiac progenitor
cells [75] and hESCs induces expression of cardiac gene
markers, including β-MHC [77]. In hESC-CMs the per-
centage of ventricular CMs in EBs overexpressing miR-499
increases significantly [77]. hESC-CMs overexpressing
miR-499 show increases in cardiac contractile proteins,including α-MHC and β-MHC, MLC2V, α-actinin and
troponin T [77]. Overexpression of miR-499 does not
induce changes in calcium handling in hESC-CMs that are
characteristic of more mature ventricular CMs [77]. There-
fore, while both miR-1 and miR-499 appear to be potent
inducers of cardiomyogenic differentiation of stem cells,
miR-499 promotes ventricular specificity after initiation of
cardiac differentiation while miR-1 induces a more mature
ventricular CM phenotype than miR-499 [77].
Histone modification
Besides miRNAs, chromatin modifications and epigenetic
changes are central to regulation of gene expression
[79,80]. Increased acetylation of amino-terminal lysine resi-
dues of histones H3 and H4 by histone acetylases correlates
with increased transcription, as the folded chromatin
becomes more accessible to transcriptional machinery
[81]. On a more genome-wide level, important chromatin
patterns of the embryonic epigenetic landscape have
been identified, with a balance between active (H3K4me3-
enriched) and silent (H3K27me3-enriched) transcription
maintained by specific histone methyltransferases [82].
Increased H3 acetylation in hESCs/human iPSC-CMs
has been shown in three-dimensional cultures and with the
administration of the histone deacetylase inhibitor trichos-
tatin A. This increase in H3 acetylation is accompanied by
augmented expression of cardiac genes, including those
encoding α-MHC, ERG1b and KCNQ1. Moreover, the
increase in H3 acetylation induces a more mature electro-
physiological profile in hESC-CMs, which enhances their
responses to IKr inhibitors E4031, nifekalant and sotalol
[83].
Our group has shown that levels of H3K4me3 were spe-
cifically enriched on cardiac gene promotors that regulate
MLC2V, MLC2A, cTNT and ANP gene expression, as well
as calcium handling genes encoding PLN, DHPR, ASPH,
TRDN, and other ion channel proteins such as SCN5A and
KCNA4 in hESC-CMs. This lysine trimethylation can be
further enhanced by the histone deacetylase inhibitor
valproic acid [84]. Indeed, valproic acid in hESC-CMs
induces expression of β-MHC protein as well as ANP, and
leads to an increase in cell size, consistent with the
induction of hypertrophy observed in fetal CMs [85].
Physical cues
In addition to biological cues for maturation, CMs in their
natural environment also possess physical properties,
including topographical cues, that induce changes in cell
morphology, as well as electrical and physical properties
[86]. Mature adult CMs in native heart are aligned in a
highly organized manner and can support fast action
potential conduction that is anisotropic with distinct trans-
verse and longitudinal velocities to support generation of
high contractile stresses [87,88]. In contrast, hPSC-CMs
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conduction velocities that are an order of magnitude lower
than those in adult human myocardium [89].
Fabricated cell culture substrates that mimic the native
environment found in the heart may improve the functional
maturation of hPSC-CMs. Indeed, microtopographical cues
have been shown to be a stronger determinant of cell orien-
tation than electrical stimulation [90]. hESC-CMs cultured
on wrinkled substrate with nano to micro topographies
show alignment and display organized sarcomeric struc-
tures with banding, and alignment of connexin-43 proteins
near cell-cell junctions [91,92]. Our group has shown that
an aligned monolayer of hESC-CMs grown on shrink film
configurable multiscale wrinkled substrate also exhibits an
anisotropic propagation with faster longitudinal conduction
velocity parallel to the direction of wrinkles than that of the
transverse conduction velocity [92]. The aligned anisotropic
hESC-CMs are more resistant to re-entrant arrhythmia [93].
Human iPSC-CMs cultured on similar aligned micro-
grooved substrate also have improved sarcomeric structure.
Calcium cycling properties show maturation with a decrease
in upstroke velocity as well as caffeine-induced calcium
release when compared to control monolayers [94].
Culturing of hPSC-CMs in three-dimensional cardiac tis-
sue patches improves alignment and electrical conduction
with a significant increase in action potential velocity and
contractile force [95]. Unlike two-dimensional constructs,
three-dimensional culturing of hESC-CMs requires the
addition of stromal cells to improve their survival and
alignment [95]. Similar three-dimensional cultures with
induced pluripotent stem cardiac progenitor cells also show
differentiation into CMs with improvement of alignment
and expression of gap-junctions and adherent molecules at
cell-cell junctions and improved electrical conduction [96].
Facilitated maturation of human pluripotent stem
cell derived-cardiomyocytes
Facilitated maturation of electrophysiological and calcium
handling properties
Efforts to understand the biology and electrophysiology of
hESC-CMs have led to the identification of a number of key
differences between hESC-CMs and their adult mature coun-
terpart. This has led to the development of different strategies
to facilitate electrophysiological maturation in hESC-CMs. As
previously described, expression of the calcium handling pro-
teins calsequestrin and phospholamban is almost completely
absent in hESC-CMs. Thus, one strategy for facilitating
maturation of calcium handling in hESC-CMs is to induce
forced expression of the ‘missing’ protein. Indeed, our labora-
tory has shown that forced expression of calsequestrin [36]
leads to functional improvements of calcium transient pa-
rameters, with increased upstroke velocity and calcium tran-
sient amplitude. However, other electrical properties of these
calsequestrin overexpressing hESC-CMs remain immature.Expression of the inward rectifying potassium channel
Kir2.1 is absent in hESC-CMs and is the key determinant of
their immature electrophysiological profile [97]. Forced
Kir2.1 expression alone sufficed to render the electrical
phenotype indistinguishable from that of primary adult ven-
tricular cells [20,97]. However, these cells continue to exhibit
immature calcium handling properties, with a small calcium
transient amplitude as well as a slow upstroke velocity.
Endogenous pacing in neonatal CMs promotes matur-
ation of both electrical and calcium handling properties. In
view of this, we have subjected hESC-CMs, which would
otherwise spontaneously beat in a weak unsustained and
sporadic manner, to field-stimulation to induce forced
electrical pacing. Electrical conditioning robustly led to
many aspects of cellular maturation of hESC-CMs, in-
cluding electrophysiological maturation without phase 4-
depolarization similar to Kir2.1 gene transfer, Ca2+-handing
maturation with increased peak Ca2+ transient amplitude
and SR Ca2+ load, and structured organization of myofila-
ments, as well as upregulation of contractile and t-tubule
biogenesis proteins [97].
Facilitated maturation of metabolic properties
As previously discussed, while hESC-CMs are metabolically
active, they possess an immature metabolic profile that is
predominantly glycolytic. In normal cardiac development,
metabolic or mitochondrial maturation does not occur
until after birth, when there is an increase in contractile
function, exposure to fatty acid as a substrate for energy,
and elevated oxygen levels. Using a combination of
β-adrenergic stimulation (isoproterenol) and fatty acid sup-
plementation to mimic post-natal developmental processes,
our laboratory was able to increase mitochondrial energet-
ics. These supplements increased mitochondrial volume as
well as mitochondrial membrane potential of the cells.
Tricarboxylic acid cycle enzyme activity was also increased
(WK and RAL, unpublished data). These results are con-
sistent with other reports that shifted energy metabolism of
human iPSC-CMs from glycolytic to predominantly oxida-
tive through the use of galactose. Galactose alone as well as
in combination with fatty acids shifts energy metabolism
from predominantly glycolytic to oxidative. Mitochondrial
reserve capacity and maximum mitochondrial capacity are
also increased with galactose and fatty acid supplementa-
tion [98,99]. While there is no change in mRNA expression
of key metabolic genes, expression of enzymes of the
electron transport chain complexes I to IV is significantly
increased in galactose and fatty acid supplemented cells;
however, the levels of expression are still significantly lower
than in adult CMs [98].
Conclusion
hESC-CMs provide an excellent source of cells for myo-
cardial repair and regeneration, although the differences
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ness for regeneration and cell replacement therapy. With
better understanding of the developmental cues leading to
maturation of hPSC-CMs, as well as recent advances in
fabrication of two-dimensional and three-dimensional
culture substrates, strategies to facilitate maturation of
these cells can be developed. This would enable the use of
both hESC-CMs and human iPSC-CMs as safe and
efficient sources for cell and tissue replacement therapy for
the treatment of heart disease.Note: This article is part of a thematic series on Cardiovascular
regeneration edited by Ronald Li. Other articles in the series can
be found online at http://stemcellres.com/series/cardiovascular.Abbreviations
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